GlassScriptPhysician profile
Imran Tahir
NPI 1194012229
$630.69
in general payments reported to CMS, 2019-2025
16 companies · $18.48 in 2025
The $18.48 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $129 · 2021: $101 · 2022: $65.88 · 2023: $83.42 · 2025: $18.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.42 · Education: $18.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.42 |
| Education | $18.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $124.83 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $76.45 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $53.54 | 2019-2022 | |
| Amicus Therapeutics, INC. | $45.99 | 2019-2021 | |
| Vifor Pharma, INC. | $43.70 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $43.66 | 2023 | Monoferric |
| Alexion Pharmaceuticals, INC. | $43.47 | 2022-2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $39.65 | 2021 | |
| Amgen INC. | $30.96 | 2019-2025 | Tavneos |
| Veloxis Pharmaceuticals, INC. | $29.75 | 2020 | |
| Daiichi Sankyo INC. | $24.54 | 2019 | |
| Horizon Therapeutics Plc | $18.33 | 2023 | Krystexxa |
| Genzyme Corporation | $17.14 | 2020 | |
| Akebia Therapeutics INC | $14.86 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.58 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Tahir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.